Lotebra Eye Drops contain a combination of Loteprednol etabonate (0.5% w/v), a corticosteroid with potent anti-inflammatory properties, and Tobramycin (0.3% w/v), an aminoglycoside antibiotic effective against a broad spectrum of bacterial pathogens. This formulation is indicated for the treatment of ocular inflammatory conditions where bacterial infection or the risk of bacterial contamination is present or suspected. Loteprednol etabonate acts by inhibiting multiple inflammatory mediators, thereby reducing redness, swelling, and discomfort associated with allergic conjunctivitis, postoperative inflammation, and other inflammatory eye disorders. Tobramycin provides bactericidal activity by binding to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and preventing bacterial proliferation. Lotebra Eye Drops are typically administered topically, with dosage and duration tailored to the severity of the condition and clinical response. Caution is advised in patients with a history of hypersensitivity to corticosteroids or aminoglycosides, and prolonged use may increase the risk of elevated intraocular pressure or secondary infections. It is essential to avoid contact with the tip of the dropper to maintain sterility. Lotebra Eye Drops should be used under the supervision of an ophthalmologist or healthcare professional experienced in managing ocular inflammatory and infectious diseases.